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Angioplasty
Background Coronary artery bypass surgery (CABG) has been considered
the therapy of choice for patients with unprotected left main (ULMT)
coronary stenoses. Selected single-center reports suggest that the results of
percutaneous intervention may now approach those of CABG.
Methods and Results To assess the results of percutaneous ULMT
treatment from a wide variety of experienced interventional centers, we
requested data on consecutive patients treated after January 1, 1994, from 25 centers. One
hundred seven patients were identified who were treated either electively (n=91) or for
acute myocardial infarction (n=16). Of patients treated electively, 25% were considered
inoperable, and 27% were considered high risk for bypass surgery. Primary treatment
included stents (50%), directional atherectomy (24%), and balloon angioplasty (20%).
Follow-up was 98.8% complete at 15±8 months. Results varied considerably, depending
on presentation and treatment. For patients with acute myocardial infarction, technical
success was achieved in 75%, and survival to hospital discharge was 31%. For elective
patients, technical success was achieved in 98.9%, and in-hospital survival was strongly
correlated with left ventricular ejection fraction (P=.003). Longer-term event (death,
infarction, or bypass surgery) -free survival was correlated with ejection fraction (P<.001)
and was inversely related to presentation with progressive or rest angina (P<.001).
Surgical candidates with ejection fractions 40% had an in-hospital survival of 98% and a
9-month event-free survival of 86±5%, whereas patients with ejection fractions <40% had
67% and 22±12% in-hospital and 9-month event-free survivals, respectively. Nine
hospital survivors (10.6%) experienced cardiac death within 6 months of hospital
discharge.
Conclusions While results for selected patients appear promising, until early post–
hospital discharge cardiac death can be better understood and minimized, percutaneous
revascularization of ULMT stenosis should not be considered an alternative to bypass
surgery for most patients. When percutaneous revascularization of ULMT is required,
directional atherectomy and stenting appear to be the preferred techniques, and follow-up
angiography 6 to 8 weeks after treatment is probably advisable.
Key Words: angioplasty • bypass • coronary disease • arteries • stents
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The favorable Veterans Administration surgical trial1 and poor initial
angioplasty2 results in patients with left main (LMT) stenoses have made
coronary artery bypass surgery (CABG) the accepted therapy of choice for
patients with LMT stenosis and no patent bypass grafts to either the left
anterior descending or left circumflex coronary systems (unprotected
LMT).3 Recent advances in percutaneous technologies and improved
results have made several centers reconsider the role of percutaneous
treatment of patients with unprotected LMT stenosis.4–6 Initial results from small single-
center reports have been favorable in most instances.7–11
Whether such a percutaneous approach can be considered an acceptable alternative to
CABG remains unknown. To evaluate this, a multicenter registry was developed to study
the initial and long-term outcome of the various subgroups of patients who might be
considered for percutaneous treatment of unprotected LMT stenoses.
Methods
Patient Population
In March 1996, the Coordinating Center for this study was established, and it requested
data from consecutive unprotected LMT patients treated beginning January 1994 from 25
high-volume clinical sites. In all, 16 sites contributed patients to this study, 8 stated that
they had not performed percutaneous intervention on any patient meeting entry criteria
for the study, and 1 chose to report its data separately.7 To minimize a potential
overwhelming contribution by any single center, centers that could contribute >30
patients were requested to submit data only for 30 consecutive patients beginning with the
most recent patient eligible.
Data Collection and Statistical Analysis
Data collected on dedicated case report forms and procedural cineangiograms were
forwarded to the coordinating center for data entry, cross-checking, and analysis.
Angiographic analysis was performed by core laboratory physicians who were blinded to
clinical outcome using electronic calipers, catheter calibration, and standard definitions.12
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The following data elements were obtained.
Baseline Angiographic Data
This information included left ventricular ejection fraction (LVEF), lesion length
(shoulder to shoulder), location of stenosis ( 30% narrowing—ostial, proximal, or distal),
"normal" reference dimension (in millimeters), number of diseased vessels, occluded right
coronary artery, and pretreatment percent stenosis.
Baseline Clinical Data
Data were collected on age, aortic insufficiency, chronic obstructive pulmonary disease,
creatinine 2 mg%, current smoker, diabetes, sex, hyperlipidemia, hypertension, jeopardy
score,13 malignancy, mitral insufficiency, peripheral vascular disease (symptomatic),
presentation (acute myocardial infarction from LMT stenosis or occlusion, cardiogenic
shock, stable angina, or unstable angina), prior bypass surgery (and years since that
operation), and recent infarction (within 2 weeks).
Stated Primary Reason for Percutaneous Therapy
The stated reasons included high risk for CABG, limited life expectancy, patient
preference in the absence of high surgical risk (common practice at several Asian
centers), and refusal by surgeons for CABG.
Treatment
Data were collected on the use of abciximab, aspirin, ß-blockers, blood product
transfusion, calcium channel blockers, cardiopulmonary support (as an adjunct to
revascularization), intra-aortic balloon pump, intubation, nitrates, other coronary sites
treated, peripheral vascular repair, procedure date, percutaneous therapy (pretreatment,
primary and bailout [separately]: balloon angioplasty, directional atherectomy, rotational
atherectomy, or stent), specific technical modifications (eg, use of intravascular
ultrasound or a perfusion balloon for angioplasty), ticlopidine, vasopressors during the
revascularization, and warfarin.
In-Hospital Outcome
This information included bypass surgery (and elective or emergency), death (and cause
of death-cardiac or noncardiac), dialysis, length of stay, maximum posttreatment creatine
kinase, myocardial infarction (and Q-wave or non–Q-wave infarction), and posttreatment
percent stenosis.
Follow-up
We collected follow-up information on CABG, death (and cause of death), myocardial
infarction, repeated percutaneous intervention, and restenosis.
Questions and Hypothesis
We prospectively sought to determine procedural, in-hospital, and long-term outcome in
the entire cohort and in patients presenting or treated with acute myocardial infarction,
directional atherectomy as primary therapy, differing stenosis location, LVEF 40% or
<40%, other devices as primary therapy, stable angina, stents as primary therapy,
surgically accepted, surgically high risk, surgically refused, unstable angina.
Data are presented as percent incidence, mean±SD, or median and interquartile range as
appropriate. Between-group comparisons were performed by use of Student's t and 2
tests and by Cox and logistic regression analyses. Statistical significance was assumed at
a value of P<.05.
Results
Patients
Data on 107 patients (0.2% of all procedures performed at these 16 hospitals during this
time period) were obtained. The patients described in this report varied widely in
condition, ranging from those with stable angina and elective intervention (44%) to those
who were deemed inoperable (27%) or presented with acute myocardial infarction and
cardiogenic shock (15%). For the 23 patients without acute infarction who were deemed
inoperable, the primary reasons listed by the clinical site were poor left ventricular
function (n=6), advanced cancer (n=3), poor target vessels (n=3), advanced age (n=2),
recent failed CABG (n=2), severe obstructive pulmonary disease (n=2), heparin allergy
(n=1), multiple prior CABG (n=1), sepsis (n=1), and not stated (n=2). For the 25 patients
at high surgical risk, the primary reasons were advanced age (n=10), poor left ventricular
function (n=8), multiple prior CABG (n=2), inoperable severe carotid artery stenosis
(n=1), multiple comorbidities (n=1), recent failed CABG (n=1), recent transient
cerebrovascular attack (n=1), and recent stroke (n=1). Baseline patient characteristics are
given in Tables 1 and 2 .
View this table:
[in this window]
[in a new window]
Table 1. Baseline Clinical Characteristics
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View this table:
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Table 2. Baseline Angiographic Characteristics
Treatment and In-Hospital Outcomes
The primary treatments used were the Palmaz-Schatz stent (n=45), directional
atherectomy (n=27), balloon angioplasty (n=21), Rotablator (n=5), the Gianturco-Roubin
I stent (n=2), the Palmaz "Biliary" stent (n=2), the ACS stent (n=1), the Cordis stent
(n=1), the Gianturco-Roubin II stent (n=1), and the NIR stent (n=1). In 11 instances of
stenting, preliminary debulking was performed (Rotablator [n=10] or directional
atherectomy [n=1]). Hemodynamic support devices were used in 68% of the patients
(intra-aortic balloon pump in 62 patients, cardiopulmonary support in 11). All patients
were pretreated with aspirin, and 26 were also treated with ticlopidine. Only 2 received
abciximab.
Choice of primary therapy appeared to depend on clinical presentation and, to a certain
extent, clinical site (see Table 3 ). Balloon angioplasty was used more often in patients
with acute infarction (adjusted odds ratio, 11.5; multivariate P=.002). Directional
atherectomy was used less commonly in nonsurgical candidates (adjusted odds ratio,
0.07; P=.014) and slightly more commonly in patients with distal LMT involvement
(adjusted odds ratio, 2.9; P=.08). Stent usage was not related to any variable studied.
Stenting of distal LMT lesions almost always was accomplished with a single stent
spanning the distal LMT and the proximal portion of the larger of the anterior descending
or circumflex arteries. All stents were implanted at pressures 12 atm. Intravascular
ultrasound use was recorded in 42.9% of elective cases.
View this table:
[in this window]
[in a new window]
Table 3. Use of Specific Primary Device Treatments
Considering all patients, technical success (final stenosis <50% diameter stenosis and
Thrombosis in Myocardial Infarction grade 3 flow) was achieved in all but 4 patients
(96.2%). Stenoses were reduced from 70±16% to 15±19% (balloon angioplasty, 37±19%;
directional atherectomy, 12±13%; and stents, 7±14%). Eleven of 16 patients (69%)
presenting with acute infarction died in hospital. Excluding these patients, in-hospital
outcomes were as follows: cardiac death, 11.0%; noncardiac death, 1.1%; Q-wave
infarction, 4.5%, non–Q-wave infarction, 10.1%; bypass surgery, 1.1%; peripheral
vascular surgery, 4.4%; blood product transfusion, 36.3%; and median length of stay, 8
days. Four deaths occurred in the catheterization laboratory, three of which occurred in
patients with LVEF <40%. Two in-hospital deaths were not believed to be
cardiovascular: One was due to sepsis and the other to pneumonia. Outcomes varied
dramatically, depending on several patient characteristics (Tables 4 and 5 ).
View this table:
[in this window]
[in a new window]
Table 4. In-Hospital Outcomes for Selected Patient Subgroups
View this table:
[in this window]
[in a new window]
Table 5. Correlates of In-Hospital Death1
Post–Hospital Discharge Outcome
Mean follow-up is currently 15±9 months. One patient was lost to follow-up after
surviving 3 months. Excluding patients presenting with infarction, 1-, 6-, and 12-month
survival and event (death, infarction, bypass surgery) -free survivals were 88.8±3.5%,
72.6±4.8%, and 70.9±5.0%, and 87.5±3.5%, 68.1±5.1%, and 68.1±5.1%, respectively.
Three deaths were directly attributable to cancer. These results varied considerably by
patient subgroup (Tables 6 and 7 and Figs 1 and 2 ).
View this table:
[in this window]
[in a new window]
Table 6. Long-term Results
View this table:
[in this window]
[in a new window]
Table 7. Independent Correlates of Event-Free Survival1
View larger version (32K):
[in this window]
[in a new window]
Figure 1. Kaplan-Meier survival curves for
selected patient subsets: A, patients presenting with
acute myocardial infarction (AMI) or noninfarct
(elective) patients; B, patients with stable angina
pectoris (AP) and rest or progressive angina
pectoris; C, patients with left ventricular ejection
fraction (LVEF) 40% or <40%; and D, patients
treated with stent or directional coronary
atherectomy (DCA).
View larger version (33K):
[in this window]
[in a new window]
Figure 2. Kaplan-Meier event-free survival curves
for selected patient sets: A, patients presenting with
acute myocardial infarction (AMI) or noninfarct
(elective) patients; B, patients with stable angina
pectoris (AP) and rest or progressive angina
pectoris; C, patients with left ventricular ejection
fraction (LVEF) 40% or <40%; and D, patients
treated with stent or directional coronary
atherectomy (DCA).
Importantly, nine hospital survivors (10.6%) died of cardiac or presumed cardiac cause
within 6 months. Most had presented with unstable angina and had been treated with
stents. All patients except one were discharged on aspirin and ticlopidine, and one was
also taking warfarin at the time of death (Table 8 ).
View this table:
[in this window]
[in a new window]
Table 8. Early Postdischarge Death (7 d-6 mo)
Overall event-free survival for patients not treated for initial myocardial infarction was
significantly correlated with low ejection fraction, presentation with progressive or rest
angina, and, to a lesser degree, use of treatments other than directional atherectomy
(Tables 6 and 7 ).
Of patients eligible for >4-month angiography, 70% had known studies, of whom 22.0%
had restenosis (stenosis 50%). In this small cohort, the only variable related to risk of
restenosis was ostial LMT location (odds ratio, 4.67; P=.07).
Discussion
Since 1976, when the Veterans Administration trial investigators reported a 5-year
survival advantage of 80% versus 64% for bypass surgery compared with medical
therapy for patients with unprotected LMT stenoses,1 this anatomy has been considered to
be an absolute indication for surgery at most centers. Current 30-day mortality after
bypass surgery in patients with LMT involvement is about 2% to 3%.14 Patients with
renal dysfunction, prior bypass surgery, advanced age, and severe heart failure are at
highest risk.14
Early reports of conventional percutaneous transluminal coronary angioplasty in this
setting did little to dissuade clinicians from this conclusion. The report of O'Keefe et al2
from the Mid-America Heart Institute in 1989 was both representative and sobering,
reporting a 55% 6-month mortality in 26 such patients.
The techniques of stenting and directional and rotational atherectomy have matured
greatly in nearly 10 years of clinical experience.15 Since the early report of Macaya et al,4
an increasing number of small-scale reports of generally successful outcomes with
unprotected LMT stenting or atherectomy have been reported.5–11 Several centers in Asia
now offer these therapies as alternatives to CABG in selected patients.
This report, although still modest in scope, is the first to study >40 patients and to
evaluate results in more than a few categories of patients. Short- and intermediate-term
results varied greatly, depending on a number of factors. Excluding presentation with
acute myocardial infarction, LVEF was the most important risk factor for in-hospital
death. In elective cases, when LVEF was 40%, mortality was only 1.7% (n=59),
whereas when LVEF was <30%, mortality was 31.8% (n=22), Three of the seven deaths
in the latter group occurred in the catheterization laboratory, attesting to the intolerance of
the impaired left ventricle to even short periods of near-global ischemia. Acceptable
event-free survival over time was also related to high LVEF but also to the absence of
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severe unstable angina at baseline and possibly to the use of directional atherectomy as
the treatment modality (Table 6 ). These data should be contrasted with those from
patients receiving thecontemporary therapy of "protected" LMT stenoses—those with
patent bypass grafts to the anterior descending or circumflex territories—in whom
survival is generally excellent.16
A disturbingly high incidence of cardiac or presumed cardiac death occurred during the
first 6 months after treatment. This occurred primarily in patients with unstable angina,
several of whom also had depressed left ventricular function, who were treated with
stents, despite the use of aspirin, ticlopidine, and high-pressure inflations. Stent
thrombosis, worsening heart failure, or arrhythmias without restenoses are plausible
explanations for this finding. It is also possible that severe restenosis may precipitate
rapidly worsening heart failure or electrical instability. It may be prudent to bring the
patient back for angiographic restudy 6 to 8 weeks after treatment to attempt to detect
early aggressive restenosis, although the benefit of such a course of action is, of course,
yet unproven.
With limited data from selected hospital sites, it is difficult to define the role of
percutaneous intervention for patients with unprotected LMT stenoses. Less experienced
sites might not be able to replicate these results. The impressions from subset analyses of
this experience need to be studied further, because the likelihood of some type I statistical
error is fairly high. If the early postdischarge events could be minimized, a strategy of
LMT directional atherectomy or stenting for patients with stable or new-onset angina and
well-preserved left ventricular dysfunction, when practiced in highly experienced centers,
would not appear to be totally unreasonable. Before such a practice could to be accepted,
randomized controlled trials comparing long-term outcome against that with bypass
surgery would need to be completed. Percutaneous intervention for inoperable patients
with LMT stenoses may be reasonable for those individuals with intractable symptoms.
All groups of patients might be expected to have improved outcomes with adjunctive use
of abciximab or related drugs, which have been demonstrated to decrease the risk of
infarction with directional atherectomy17 and emergency stenting18 and are under study in
the setting of elective stenting.
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